Active — Not RecruitingNot Applicable

Interventional Ablation for Early-stage Lung Cancer

China656 participantsStarted 2025-04-12

Plain-language summary

What is this study about? This clinical trial aims to compare two treatments for high-risk lung nodules or early-stage lung cancer: interventional ablation (a minimally invasive procedure that destroys tumors with heat or cold) and surgical resection (surgery to remove the tumor). The goal is to determine if ablation is as safe and effective as surgery while preserving more lung function. Why is this important? Lung cancer is a leading cause of cancer deaths worldwide. Early detection improves survival, but surgery can damage lung function. Ablation (e.g., microwave, cryotherapy) is less invasive than surgery and may offer similar outcomes with faster recovery. However, more evidence is needed to confirm its role in early-stage disease.

Who can participate

Age range20 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age of 20-79 years;
✓. Eastern Cooperative Oncology Group Physical Status (ECOG PS) score of 0-2;
✓. Enhanced CT of the chest: suspicious malignant signs of lung nodules, such as lobar sign, burr sign, pleural depression sign, bronchial insufflation sign, vacuolar sign, vascular cluster sign, or signs of twisted dilatation of blood vessels within the nodule and cystic cavity type, with no more than 3 lesions bilaterally or unilaterally, and no lymph node metastasis;
✓. Thin-section CT of the chest: maximum diameter of the lesion \> 5mm ≤ 2cm, solid/tumour ratio CTR ≤ 0.25;
✓. Adequate haematological, renal and hepatic functions:
✓. Haematology: absolute neutrophil count (ANC) ≥1.5×109/L, platelet (PLT) ≥100×109/L, haemoglobin (HGB) ≥9 g/dL;
✓. Liver function: serum total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤2.5 times the ULN, serum albumin (ALB) ≥2.8 g/dL;
✓. Renal function: serum creatinine (Cr) ≤ 1.5 x ULN, or creatinine clearance ≥ 40 mL/min;

Exclusion criteria

What they're measuring

relapse-free survival, RFS

Timeframe: Three years, five years

Trial details

NCT IDNCT07005999

SponsorGuangzhou Institute of Respiratory Disease

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-12-21

View on ClinicalTrials.gov More Lung Cancer (NSCLC) trials